drugset / Trial / NCT00686621

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)

NCT00686621 ↗

Expanded access Approved for marketing Merck Sharp & Dohme LLC

Summary

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for which there are no effective therapies; 3) with a prior history of serious, severe, or life-threatening toxicities while receiving standard antifungal therapies, or 4) with pre-existing organ dysfunction which precludes the use of standard antifungal therapies.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 200 mg Oral
Subject Posaconazole Small molecule 400 mg Oral